Literature DB >> 24462695

Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.

Young-Man Kwon1, Hye Suk Hwang1, Jong Seok Lee1, Eun-Ju Ko1, Si-Eun Yoo1, Min-Chul Kim2, Yu-Na Lee1, Ki-Hye Kim1, Jae-Min Song3, Sujin Lee4, Martin L Moore4, Sang-Moo Kang5.   

Abstract

Maternal immunization of mice with formalin inactivated respiratory syncytial virus (FI-RSV) resulted in the passive transfer of RSV antibodies but not cellular components to the offspring. The offspring born to FI-RSV immunized mothers showed serum RSV neutralizing activity, effectively controlled lung viral loads without vaccine-enhanced disease, did not induce pulmonary eosinophilia, and cytokine producing cells after live RSV infection. Therefore, this study provides evidence that maternal immunization provides an in vivo model in investigating the roles of antibodies independent of cellular components.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FI-RSV; Maternal antibodies; Passive immunization; Vaccine enhanced disease

Mesh：

Substances：

Year:  2014        PMID： 24462695      PMCID： PMC3960005          DOI： 10.1016/j.antiviral.2014.01.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  30 in total

1.  Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine.

Authors:  Gregory A Prince; Spencer J Curtis; Kevin C Yim; David D Porter
Journal:  J Gen Virol       Date:  2001-12       Impact factor: 3.891

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.

Authors:  X Li; S Sambhara; C X Li; L Ettorre; I Switzer; G Cates; O James; M Parrington; R Oomen; R P Du; M Klein
Journal:  Virology       Date:  2000-03-30       Impact factor: 3.616

5.  Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs.

Authors:  A Chatterjee; C J Harrison; W J Britt; C Bewtra
Journal:  J Infect Dis       Date:  2001-04-27       Impact factor: 5.226

Review 6.  Transfer of antibody via mother's milk.

Authors:  Philippe Van de Perre
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

7.  Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; L A Boutilier; N Campeol; K Melville; Todd S Laughlin; C K Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

9.  Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.

Authors:  L Clark Paramore; Vincent Ciuryla; Gabrielle Ciesla; Larry Liu
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit.

Authors:  S Alan; E Okulu; A Kiliç; B Atasay; S Arsan
Journal:  J Hosp Infect       Date:  2012-06-20       Impact factor: 3.926
View more
  14 in total

1.  Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.

Authors:  Eun-Ju Ko; Young-Tae Lee; Ki-Hye Kim; Youri Lee; Yu-Jin Jung; Min-Chul Kim; Yu-Na Lee; Taeuk Kang; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-11-23       Impact factor: 5.422

2.  Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.

Authors:  Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Min-Chul Kim; Eun-Ju Ko; Jong Seok Lee; Youri Lee; Sang-Moo Kang
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

3.  Metabolic pathways of lung inflammation revealed by high-resolution metabolomics (HRM) of H1N1 influenza virus infection in mice.

Authors:  Joshua D Chandler; Xin Hu; Eun-Ju Ko; Soojin Park; Young-Tae Lee; Michael Orr; Jolyn Fernandes; Karan Uppal; Sang-Moo Kang; Dean P Jones; Young-Mi Go
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-08-24       Impact factor: 3.619

4.  Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Min-Kyoung Cho; Young-Man Kwon; Jong Seok Lee; Richard K Plemper; Sang-Moo Kang
Journal:  Virology       Date:  2014-12-30       Impact factor: 3.616

5.  Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Jong Seok Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-12-13       Impact factor: 5.970

6.  Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

Authors:  Young-Man Kwon; Youri Lee; Ki Hye Kim; Yu Jin Jung; Zhuo Li; Subbiah Jeeva; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-09-18       Impact factor: 3.641

7.  Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.

Authors:  Anurag Sharma; Rebecca Wendland; Biin Sung; Wenzhu Wu; Thomas Grunwald; Stefan Worgall
Journal:  Vaccine       Date:  2014-08-26       Impact factor: 3.641

8.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

9.  Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.

Authors:  Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Yu-Jin Jung; Youri Lee; Jong Seok Lee; Yu-Na Lee; Soojin Park; Sang-Moo Kang
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 10.  Pregnancy and infection: using disease pathogenesis to inform vaccine strategy.

Authors:  Meghan S Vermillion; Sabra L Klein
Journal:  NPJ Vaccines       Date:  2018-02-01       Impact factor: 7.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.